Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-10-10

AUTHORS

Feng Lu, Katie J. Suda, Katherine E. Marks

ABSTRACT

Background For the past 30 years, clinical trials have been increasingly conducted in developing countries. These trials allow results to be generalizable to similar populations, offer access to treatment for patients in need, and examine diseases with differing patterns than developed countries. However, the characteristics of antineoplastic clinical trials and recent trends in study location in developing countries are unknown. Objective The primary objective was to evaluate the location, study phase, results, funding source, and ethics board approval of randomized double-blind controlled clinical trials evaluating antineoplastic agents by geographic location. Setting This is a retrospective evaluation of studies indexed in the PubMed/Medline database published in 2007–2011. Methods Clinical trials were identified with the search terms “drug therapy”, “antineoplastic agents” and “double blind method” and limited to English language, human, and randomized controlled trial. Main Outcome Measure We assessed frequencies of characteristics of antineoplastic clinical trials. Results A total of 116 trials evaluating antineoplastic drug therapy were identified. The highest frequency of clinical trials were published in 2009 (27.6 %), followed by 2011 (23.3 %), 2010 (20.7 %), 2007 (14.6 %), and 2008 (13.8 %). According to geographic region, 33.8 % were conducted in North America, followed by Europe (31.5 %) and Asia (16.2 %). Based on economic status, the majority (77.8 %) of clinical trial locations were in developed countries and 22.2 % were in developing countries. No significant difference was found between study locations in developed countries and developing countries from 2007 to 2011. When comparing studies conducted in developing and developed countries, there was no difference in the year published, study phase, results, funding source, or investigational review board approval and informed consent. Studies conducted in developed countries were significantly more likely to be single country studies (p = 0.02) and published in a journal with an impact factor greater than 10 (p = 0.013) when compared to studies conducted in developing countries. Conclusions Based on economic status, there was no significant location change of antineoplastic clinical trials from 2007 to 2011. Clinical trials conducted in developing countries were more often multi-country studies and published in journals with lower impact factors. More... »

PAGES

87-91

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11096-012-9711-6

DOI

http://dx.doi.org/10.1007/s11096-012-9711-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1036670838

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/23054141


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Developed Countries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Developing Countries", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.267301.1", 
          "name": [
            "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Feng", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.267301.1", 
          "name": [
            "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Suda", 
        "givenName": "Katie J.", 
        "id": "sg:person.0601042140.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601042140.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA", 
          "id": "http://www.grid.ac/institutes/grid.267301.1", 
          "name": [
            "College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marks", 
        "givenName": "Katherine E.", 
        "type": "Person"
      }
    ], 
    "datePublished": "2012-10-10", 
    "datePublishedReg": "2012-10-10", 
    "description": "Background For the past 30\u00a0years, clinical trials have been increasingly conducted in developing countries. These trials allow results to be generalizable to similar populations, offer access to treatment for patients in need, and examine diseases with differing patterns than developed countries. However, the characteristics of antineoplastic clinical trials and recent trends in study location in developing countries are unknown. Objective The primary objective was to evaluate the location, study phase, results, funding source, and ethics board approval of randomized double-blind controlled clinical trials evaluating antineoplastic agents by geographic location. Setting This is a retrospective evaluation of studies indexed in the PubMed/Medline database published in 2007\u20132011. Methods Clinical trials were identified with the search terms \u201cdrug therapy\u201d, \u201cantineoplastic agents\u201d and \u201cdouble blind method\u201d and limited to English language, human, and randomized controlled trial. Main Outcome Measure We assessed frequencies of characteristics of antineoplastic clinical trials. Results A total of 116 trials evaluating antineoplastic drug therapy were identified. The highest frequency of clinical trials were published in 2009 (27.6\u00a0%), followed by 2011 (23.3\u00a0%), 2010 (20.7\u00a0%), 2007 (14.6\u00a0%), and 2008 (13.8\u00a0%). According to geographic region, 33.8\u00a0% were conducted in North America, followed by Europe (31.5\u00a0%) and Asia (16.2\u00a0%). Based on economic status, the majority (77.8\u00a0%) of clinical trial locations were in developed countries and 22.2\u00a0% were in developing countries. No significant difference was found between study locations in developed countries and developing countries from 2007 to 2011. When comparing studies conducted in developing and developed countries, there was no difference in the year published, study phase, results, funding source, or investigational review board approval and informed consent. Studies conducted in developed countries were significantly more likely to be single country studies (p\u00a0=\u00a00.02) and published in a journal with an impact factor greater than 10 (p\u00a0=\u00a00.013) when compared to studies conducted in developing countries. Conclusions Based on economic status, there was no significant location change of antineoplastic clinical trials from 2007 to 2011. Clinical trials conducted in developing countries were more often multi-country studies and published in journals with lower impact factors.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11096-012-9711-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1044817", 
        "issn": [
          "2210-7703", 
          "2210-7711"
        ], 
        "name": "International Journal of Clinical Pharmacy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "35"
      }
    ], 
    "keywords": [
      "clinical trials", 
      "drug therapy", 
      "board approval", 
      "antineoplastic agents", 
      "Methods Clinical trials", 
      "antineoplastic drug therapy", 
      "PubMed/MEDLINE database", 
      "Investigational review board approval", 
      "main outcome measures", 
      "double-blind method", 
      "review board approval", 
      "ethics board approval", 
      "study phase", 
      "frequency of characteristics", 
      "outcome measures", 
      "retrospective evaluation", 
      "MEDLINE database", 
      "economic status", 
      "informed consent", 
      "trials", 
      "search terms", 
      "multi-country study", 
      "significant differences", 
      "similar populations", 
      "therapy", 
      "funding sources", 
      "primary objective", 
      "approval", 
      "status", 
      "study location", 
      "geographic location", 
      "patients", 
      "geographic regions", 
      "high frequency", 
      "agents", 
      "study", 
      "years", 
      "disease", 
      "English language", 
      "blind method", 
      "treatment", 
      "factors", 
      "total", 
      "differences", 
      "country studies", 
      "consent", 
      "conclusion", 
      "lower impact factors", 
      "humans", 
      "majority", 
      "population", 
      "countries", 
      "frequency", 
      "evaluation", 
      "results", 
      "database", 
      "background", 
      "measures", 
      "location", 
      "impact factor", 
      "changes", 
      "objective", 
      "recent trends", 
      "characteristics", 
      "journals", 
      "need", 
      "trial locations", 
      "patterns", 
      "access", 
      "North America", 
      "single-country studies", 
      "trends", 
      "phase", 
      "region", 
      "source", 
      "method", 
      "Asia", 
      "location changes", 
      "Europe", 
      "America", 
      "terms", 
      "language", 
      "antineoplastic clinical trials", 
      "clinical trial locations", 
      "significant location change", 
      "antineoplastic agent clinical trials", 
      "agent clinical trials"
    ], 
    "name": "Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries", 
    "pagination": "87-91", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1036670838"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11096-012-9711-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "23054141"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11096-012-9711-6", 
      "https://app.dimensions.ai/details/publication/pub.1036670838"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:26", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_562.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11096-012-9711-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9711-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9711-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9711-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11096-012-9711-6'


 

This table displays all metadata directly associated to this object as RDF triples.

189 TRIPLES      21 PREDICATES      120 URIs      112 LITERALS      14 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11096-012-9711-6 schema:about N2e5a4613248144ce8af6f0b800dd4aa8
2 N4a07bb34cda241f9985edb312acaddda
3 N5675ae3189d24c5a8a99f0b4372d149d
4 N6775071f14104790afb5ae611d5358e8
5 Na9d62790628d43d6aa99235febd43219
6 Nbae2a7ec30d24665b7213a27570b4d49
7 Nd7ce145de24d435e867f44993a538709
8 anzsrc-for:11
9 anzsrc-for:1117
10 schema:author Nc2ec55a63f184617a5416c32907abb67
11 schema:datePublished 2012-10-10
12 schema:datePublishedReg 2012-10-10
13 schema:description Background For the past 30 years, clinical trials have been increasingly conducted in developing countries. These trials allow results to be generalizable to similar populations, offer access to treatment for patients in need, and examine diseases with differing patterns than developed countries. However, the characteristics of antineoplastic clinical trials and recent trends in study location in developing countries are unknown. Objective The primary objective was to evaluate the location, study phase, results, funding source, and ethics board approval of randomized double-blind controlled clinical trials evaluating antineoplastic agents by geographic location. Setting This is a retrospective evaluation of studies indexed in the PubMed/Medline database published in 2007–2011. Methods Clinical trials were identified with the search terms “drug therapy”, “antineoplastic agents” and “double blind method” and limited to English language, human, and randomized controlled trial. Main Outcome Measure We assessed frequencies of characteristics of antineoplastic clinical trials. Results A total of 116 trials evaluating antineoplastic drug therapy were identified. The highest frequency of clinical trials were published in 2009 (27.6 %), followed by 2011 (23.3 %), 2010 (20.7 %), 2007 (14.6 %), and 2008 (13.8 %). According to geographic region, 33.8 % were conducted in North America, followed by Europe (31.5 %) and Asia (16.2 %). Based on economic status, the majority (77.8 %) of clinical trial locations were in developed countries and 22.2 % were in developing countries. No significant difference was found between study locations in developed countries and developing countries from 2007 to 2011. When comparing studies conducted in developing and developed countries, there was no difference in the year published, study phase, results, funding source, or investigational review board approval and informed consent. Studies conducted in developed countries were significantly more likely to be single country studies (p = 0.02) and published in a journal with an impact factor greater than 10 (p = 0.013) when compared to studies conducted in developing countries. Conclusions Based on economic status, there was no significant location change of antineoplastic clinical trials from 2007 to 2011. Clinical trials conducted in developing countries were more often multi-country studies and published in journals with lower impact factors.
14 schema:genre article
15 schema:inLanguage en
16 schema:isAccessibleForFree false
17 schema:isPartOf N641c43fc6a624ef9a247bd1d66cc6904
18 N89107d5acce94f478e7c7d9b898ea48f
19 sg:journal.1044817
20 schema:keywords America
21 Asia
22 English language
23 Europe
24 Investigational review board approval
25 MEDLINE database
26 Methods Clinical trials
27 North America
28 PubMed/MEDLINE database
29 access
30 agent clinical trials
31 agents
32 antineoplastic agent clinical trials
33 antineoplastic agents
34 antineoplastic clinical trials
35 antineoplastic drug therapy
36 approval
37 background
38 blind method
39 board approval
40 changes
41 characteristics
42 clinical trial locations
43 clinical trials
44 conclusion
45 consent
46 countries
47 country studies
48 database
49 differences
50 disease
51 double-blind method
52 drug therapy
53 economic status
54 ethics board approval
55 evaluation
56 factors
57 frequency
58 frequency of characteristics
59 funding sources
60 geographic location
61 geographic regions
62 high frequency
63 humans
64 impact factor
65 informed consent
66 journals
67 language
68 location
69 location changes
70 lower impact factors
71 main outcome measures
72 majority
73 measures
74 method
75 multi-country study
76 need
77 objective
78 outcome measures
79 patients
80 patterns
81 phase
82 population
83 primary objective
84 recent trends
85 region
86 results
87 retrospective evaluation
88 review board approval
89 search terms
90 significant differences
91 significant location change
92 similar populations
93 single-country studies
94 source
95 status
96 study
97 study location
98 study phase
99 terms
100 therapy
101 total
102 treatment
103 trends
104 trial locations
105 trials
106 years
107 schema:name Geographic location of antineoplastic agent clinical trials conducted in developed and developing countries
108 schema:pagination 87-91
109 schema:productId N196dae9c7f024b2e82f51272a51ca11c
110 Nbc211a89aff94930bf126837181adc4d
111 Nbed6cbd98b474ac8be940df8ead8b03d
112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036670838
113 https://doi.org/10.1007/s11096-012-9711-6
114 schema:sdDatePublished 2021-12-01T19:26
115 schema:sdLicense https://scigraph.springernature.com/explorer/license/
116 schema:sdPublisher Naa9e5e781f4847648dfe6c64898d3a2c
117 schema:url https://doi.org/10.1007/s11096-012-9711-6
118 sgo:license sg:explorer/license/
119 sgo:sdDataset articles
120 rdf:type schema:ScholarlyArticle
121 N196dae9c7f024b2e82f51272a51ca11c schema:name doi
122 schema:value 10.1007/s11096-012-9711-6
123 rdf:type schema:PropertyValue
124 N2e5a4613248144ce8af6f0b800dd4aa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Developing Countries
126 rdf:type schema:DefinedTerm
127 N4a07bb34cda241f9985edb312acaddda schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Humans
129 rdf:type schema:DefinedTerm
130 N5675ae3189d24c5a8a99f0b4372d149d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Antineoplastic Agents
132 rdf:type schema:DefinedTerm
133 N5718afe8ca0649af83c17dc2626fa0f4 rdf:first sg:person.0601042140.08
134 rdf:rest Ndfee24aa72da42e9a7937eecbd115b17
135 N641c43fc6a624ef9a247bd1d66cc6904 schema:volumeNumber 35
136 rdf:type schema:PublicationVolume
137 N6775071f14104790afb5ae611d5358e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Developed Countries
139 rdf:type schema:DefinedTerm
140 N89107d5acce94f478e7c7d9b898ea48f schema:issueNumber 1
141 rdf:type schema:PublicationIssue
142 Na9d62790628d43d6aa99235febd43219 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Neoplasms
144 rdf:type schema:DefinedTerm
145 Naa9e5e781f4847648dfe6c64898d3a2c schema:name Springer Nature - SN SciGraph project
146 rdf:type schema:Organization
147 Nb2e85c0f73344468b247c8cf8ebbf3b3 schema:affiliation grid-institutes:grid.267301.1
148 schema:familyName Lu
149 schema:givenName Feng
150 rdf:type schema:Person
151 Nbae2a7ec30d24665b7213a27570b4d49 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Double-Blind Method
153 rdf:type schema:DefinedTerm
154 Nbc211a89aff94930bf126837181adc4d schema:name dimensions_id
155 schema:value pub.1036670838
156 rdf:type schema:PropertyValue
157 Nbed6cbd98b474ac8be940df8ead8b03d schema:name pubmed_id
158 schema:value 23054141
159 rdf:type schema:PropertyValue
160 Nc2ec55a63f184617a5416c32907abb67 rdf:first Nb2e85c0f73344468b247c8cf8ebbf3b3
161 rdf:rest N5718afe8ca0649af83c17dc2626fa0f4
162 Nce88d3ce3115479d9a070d25663d65e0 schema:affiliation grid-institutes:grid.267301.1
163 schema:familyName Marks
164 schema:givenName Katherine E.
165 rdf:type schema:Person
166 Nd7ce145de24d435e867f44993a538709 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Randomized Controlled Trials as Topic
168 rdf:type schema:DefinedTerm
169 Ndfee24aa72da42e9a7937eecbd115b17 rdf:first Nce88d3ce3115479d9a070d25663d65e0
170 rdf:rest rdf:nil
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
175 schema:name Public Health and Health Services
176 rdf:type schema:DefinedTerm
177 sg:journal.1044817 schema:issn 2210-7703
178 2210-7711
179 schema:name International Journal of Clinical Pharmacy
180 schema:publisher Springer Nature
181 rdf:type schema:Periodical
182 sg:person.0601042140.08 schema:affiliation grid-institutes:grid.267301.1
183 schema:familyName Suda
184 schema:givenName Katie J.
185 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601042140.08
186 rdf:type schema:Person
187 grid-institutes:grid.267301.1 schema:alternateName College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA
188 schema:name College of Pharmacy, University of Tennessee Health Science Center, 881 Madison Avenue, #340, 38163, Memphis, TN, USA
189 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...